ClinicalTrials.gg
CompletedNCT01321554SELECTUpdated Jun 22, 2023Results posted

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

A Phase 3 interventional study of Lenvatinib and Placebo in Thyroid Cancer, sponsored by Eisai Inc.. Completed at 155 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies testing lenvatinib in Thyroid Neoplasms — 6 open to participants now, 7 under way, none of them phase 3. lenvatinib · Thyroid Neoplasms.

Enrollment
2nd of 17
392 · median 35
Started
2011
the only one that year
Phase 3
2 of 17
none open now
Registered
2nd of 17
by date
Lead sponsor
3 of 17
Eisai Inc.

Among the 17 studies testing lenvatinib in Thyroid Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2011, is one of 2 in phase 3, and was the 2nd registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

6 of the 17 studies testing lenvatinib in Thyroid Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing lenvatinib in Thyroid Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a Prerandomization Phase (screening and baseline period), a Randomization Phase (double-blind treatment period), and an Extension Phase (Optional Open Label (OOL) Lenvatinib Treatment Period and a follow-up period).

Read the detailed description

Randomization Phase: Participants will receive blinded study drug (lenvatinib/placebo) in 2:1 ratio until documentation of disease progression (confirmed by independent imaging review), development of unacceptable toxicity, or withdrawal of consent. After having completed the primary analysis, subjects treated with lenvatinib who have not experienced disease progression may request to continue open label lenvatinib at the same dose, according to the clinical judgment of the investigator. Participants who discontinue treatment for any reason other than disease progression will be followed in the Randomization Phase until disease progression or start of another anticancer treatment; these participants then enter the Extension Phase for survival follow-up. Extension Phase: Participants in the placebo arm who have disease progression confirmed by IIR could request to enter the OOL Lenvatinib Treatment Period and receive lenvatinib treatment. Participants will receive lenvatinib treatment until disease progression (investigator's assessment), development of intolerable toxicity, or withdrawal of consent. Participants who had disease progression during the Randomization Phase and did not enter the OOL Lenvatinib Treatment Period and all participants who discontinued lenvatinib treatment in the OOL Lenvatinib Treatment Period will enter the follow-up period. Participants will be followed for survival, and all anticancer treatments will be recorded until the time of death.

03

Conditions studied

  • Thyroid Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed diagnosis of one of the following DTC subtypes: Papillary thyroid cancer (PTC) or follicular thyroid cancer (FTC).
  2. according to ( 1.1) and confirmed by central radiographic review.
  3. 131 I-/resistant disease.
  4. Evidence of disease progression within 12 months prior to signing (+1 month screening window).
  5. Prior treatment with 0 or 1 vascular endothelial growth-factor (VEGF) or vascular endothelial growth-factor receptors (VEGFR) targeted therapy.
  6. Adequate renal, liver, bone marrow, and blood coagulation function, as defined in the protocol.

Exclusion criteria

Exclusion criteria:

  1. Anaplastic or medullary carcinoma of the thyroid
  2. 2 or more prior VEGF/ VEGFR-targeted therapies
  3. Received any anticancer treatment within 21 days or any agent within 30 days prior to the first dose of study drug.

Inclusion criteria for OOL Lenvatinib Treatment Period :

Participants were eligible for lenvatinib treatment in the OOL Lenvatinib Treatment Period if the met the following criteria:

  1. Placebo-treated participants in the Randomization Phase who had progressive disease (PD) confirmed by IIR, and who requested treatment with lenvatinib.
  2. Participants who continued to satisfy specified inclusion and exclusion criteria as presented in the study protocol.
  3. Participants with maximum interval between the day of confirmation of PD by IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period of less than or equal to 3 months.
  4. No systemic anticancer treatment during the interval between the day of confirmation of PD by the IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
392 participants (actual)

Study arms

  • Experimental
    Lenvatinib (Randomization Phase)

    Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.

    Drug: Lenvatinib

  • Placebo comparator
    Placebo (Randomization Phase)

    Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.

    Drug: Placebo

  • Experimental
    Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)

    Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.

    Drug: Lenvatinib

  • Experimental
    Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)

    Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.

    Drug: Lenvatinib

Interventions

  • Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.

    Also known as: Lenvatinib (Lenvima, E7080)

  • DrugPlacebo

    Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.

  • Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity. The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg.

    Also known as: Lenvatinib (Lenvima, E7080)

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded IIR using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20 percent (%) relative increase and 5 millimeter (mm) absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions.

    Time frame: Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR, defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by blinded IIR using RECIST 1.1 for target lesions and assessed by magnetic resonance imaging/computed tomography (MRI/CT) scans (for double blind treatment period i.e. Randomization Phase). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.

    Time frame: Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years

  2. Overall Survival (OS)

    Overall survival measured from the date of randomization until date of death from any cause. Overall survival is adjusted with rank preserving structural failure time.

    Time frame: Date of randomization until date of death from any cause, assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years

  3. Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve

    Time frame: Cycle 1 Days 1 and 15: 0-10 hours postdose; Cycle 2 Day 1: 0-12 hour postdose

07

Results

Posted Dec 12, 2016

Participant flow

Participants took part in the study at 117 investigative sites in Europe, North America, Asia Pacific, Japan, and Latin America from 17 March 2011 to 19 March 2019.

Randomization Phase
Participant flow — Randomization Phase
MilestoneRandomization Phase: Lenvatinib 24 mgRandomization Phase: PlaceboOOL, Treatment Period: Lenvatinib 24 mgOOL, Treatment Period: Lenvatinib 20 mg
Started26113100
Completed26113100
Not completed0000
OOL Lenvatinib Treatment Period
Participant flow — OOL Lenvatinib Treatment Period
MilestoneRandomization Phase: Lenvatinib 24 mgRandomization Phase: PlaceboOOL, Treatment Period: Lenvatinib 24 mgOOL, Treatment Period: Lenvatinib 20 mg
Started008530
Completed008530
Not completed0000

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded IIR using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20 percent (%) relative increase and 5 millimeter (mm) absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions.

Time frame:
Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
Reported as:
Median · months
Progression Free Survival (PFS)
monthsRandomization Phase: Lenvatinib 24 mgRandomization Phase: Placebo
Progression Free Survival (PFS)18.3 (15.1 to NA)3.6 (2.2 to 3.7)
Statistical analysis
  • Randomization Phase: Lenvatinib 24 mg vs Randomization Phase: Placebo · Cox proportional hazard: 0.21 · 99% CI 0.14 to 0.31
SecondaryOverall Response Rate (ORR)

ORR, defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by blinded IIR using RECIST 1.1 for target lesions and assessed by magnetic resonance imaging/computed tomography (MRI/CT) scans (for double blind treatment period i.e. Randomization Phase). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.

Time frame:
Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsRandomization Phase: Lenvatinib 24 mgRandomization Phase: Placebo
Overall Response Rate (ORR)64.8 (59.0 to 70.5)1.5 (0.0 to 3.6)
SecondaryOverall Survival (OS)

Overall survival measured from the date of randomization until date of death from any cause. Overall survival is adjusted with rank preserving structural failure time.

Time frame:
Date of randomization until date of death from any cause, assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
Reported as:
Median · months
Overall Survival (OS)
monthsRandomization Phase: Lenvatinib 24 mgRandomization Phase: Placebo
Overall Survival (OS)NA (22.0 to NA)NA (14.3 to NA)
SecondaryPharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve
Time frame:
Cycle 1 Days 1 and 15: 0-10 hours postdose; Cycle 2 Day 1: 0-12 hour postdose
Reported as:
Median · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve
nanogram*hour per milliliter (ng*h/mL)Randomization Phase: Lenvatinib 24 mg
Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve3490 (1410 to 10700)

Adverse events

Collected over For each participant, from the first dose till 30 days after the last dose up to approximately 8 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomization Phase: Lenvatinib 24 mg161/261 (61.7%)171/261 (65.5%)259/261 (99.2%)
Randomization Phase: Placebo13/16 (81.3%)31/131 (23.7%)118/131 (90.1%)
OOL, Treatment Period: Lenvatinib 24 mg62/85 (72.9%)62/85 (72.9%)84/85 (98.8%)
OOL, Treatment Period: Lenvatinib 20 mg15/30 (50%)16/30 (53.3%)29/30 (96.7%)
Most frequent serious events
Showing 10 of 289
Most frequent serious events
EventRandomization Phase: Lenvatinib 24 mgRandomization Phase: PlaceboOOL, Treatment Period: Lenvatinib 24 mgOOL, Treatment Period: Lenvatinib 20 mg
ConstipationGastrointestinal disorders1/2611/1310/852/30
Lung infectionInfections and infestations4/2610/1311/852/30
PneumoniaInfections and infestations12/2613/1315/852/30
Abdominal painGastrointestinal disorders3/2610/1314/850/30
HypertensionVascular disorders10/2610/1311/851/30
DyspnoeaRespiratory, thoracic and mediastinal disorders6/2615/1313/851/30
Atrial fibrillationCardiac disorders4/2610/1313/850/30
Back painMusculoskeletal and connective tissue disorders3/2610/1313/850/30
Cerebrovascular accidentNervous system disorders2/2610/1313/851/30
DeathGeneral disorders2/2611/1313/850/30
Most frequent other events
Showing 10 of 106
Most frequent other events
EventRandomization Phase: Lenvatinib 24 mgRandomization Phase: PlaceboOOL, Treatment Period: Lenvatinib 24 mgOOL, Treatment Period: Lenvatinib 20 mg
DiarrhoeaGastrointestinal disorders182/26122/13155/8521/30
HypertensionVascular disorders181/26119/13152/8521/30
Weight decreasedInvestigations142/26120/13144/8518/30
Decreased appetiteMetabolism and nutrition disorders148/26124/13143/8511/30
NauseaGastrointestinal disorders127/26134/13134/8512/30
FatigueGeneral disorders116/26133/13135/8513/30
StomatitisGastrointestinal disorders100/2619/13128/8513/30
VomitingGastrointestinal disorders100/26119/13136/859/30
HeadacheNervous system disorders105/26115/13119/8510/30
ArthralgiaMusculoskeletal and connective tissue disorders85/2619/13119/8512/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Randomization Phase: Lenvatinib 24 mgRandomization Phase: PlaceboTotal
Geometric mean62.1 ± 10.5761.5 ± 10.0961.9 ± 10.40
Sex: Female, Male
Sex: Female, Male(Participants)Randomization Phase: Lenvatinib 24 mgRandomization Phase: PlaceboTotal
Female13656192
Male12575200
08

Study locations

155 sites
  • Facility 1
    Little Rock, Arkansas, United States
  • Facility 1
    La Jolla, California, United States
  • Facility 1
    Los Gatos, California, United States
  • Facility 1
    Mission Viejo, California, United States
  • Facility 1
    Orange, California, United States
  • Facility 2
    Orange, California, United States
  • Facility 1
    Sacramento, California, United States
  • Facility 1
    Torrance, California, United States
  • Facility 1
    Aurora, Colorado, United States
  • Facility 1
    Washington, District of Columbia, United States
  • Facility 1
    Orlando, Florida, United States
  • Facility 1
    Weston, Florida, United States
  • Facility 1
    Chicago, Illinois, United States
  • Facility 2
    Chicago, Illinois, United States
  • Facility 1
    Indianapolis, Indiana, United States
  • Facility 1
    Lexington, Kentucky, United States
  • Facility 1
    Baltimore, Maryland, United States
  • Facility 1
    Boston, Michigan, United States
  • Facility 2
    Boston, Michigan, United States
  • Facility 1
    Detroit, Michigan, United States
  • Facility 1
    Lansing, Michigan, United States
  • Facility 1
    Minneapolis, Minnesota, United States
  • Facility 1
    Columbia, Missouri, United States
  • Facility 1
    Omaha, Nebraska, United States
  • Facility 1
    Lebanon, New Hampshire, United States
  • Facility 1
    Morristown, New Jersey, United States
  • Facility 1
    Neptune, New Jersey, United States
  • Facility 1
    Bronx, New York, United States
  • Facility 1
    New York, New York, United States
  • Facility 2
    New York, New York, United States
  • Facility 1
    Columbus, Ohio, United States
  • Facility 1
    Portland, Oregon, United States
  • Facility 1
    Philadelphia, Pennsylvania, United States
  • Facility 2
    Philadelphia, Pennsylvania, United States
  • Facility 1
    Houston, Texas, United States
  • Facility 1
    Seattle, Washington, United States
  • Facility 1
    Morgantown, West Virginia, United States
  • Facility 1
    Milwaukee, Wisconsin, United States
  • Facility 1
    Rosario, Argentina
  • Facility 1
    San Salvador de Jujuy, Argentina
  • Facility 1
    Tucuman, Argentina
  • Facility 1
    Saint Leonards, New South Wales, Australia
  • Facility 1
    Herston, Queensland, Australia
  • Facility 1
    Hobart, Tasmania, Australia
  • Facility 1
    Melbourne, Victoria, Australia
  • Facility 1
    Heidelberg, Australia
  • Facility 1
    Wien, Austria
  • Facility 1
    Bruxelles, Belgium
  • Facility 1
    Edegem, Belgium
  • Facility 1
    Namur, Belgium
  • Facility 1
    Brasilia, Brazil
  • Facility 1
    Joinville, Brazil
  • Facility 1
    Novo Hamburgo, Brazil
  • Facility 1
    Rio de Janeiro, Brazil
  • Facility 1
    Salvador, Brazil
  • Facility 1
    Sao Paulo, Brazil
  • Facility 2
    Sao Paulo, Brazil
  • Facility 1
    London, Ontario, Canada
  • Facility 1
    Toronto, Ontario, Canada
  • Facility 1
    Montreal, Quebec, Canada
  • Facility 1
    Quebec, Canada
  • Facility 1
    Santiago, Chile
  • Facility 2
    Santiago, Chile
  • Facility 3
    Santiago, Chile
  • Facility 1
    Temuco, Chile
  • Facility 1
    Vina del Mar, Chile
  • Facility 1
    Olomouc, Czechia
  • Facility 1
    Odense, Denmark
  • Facility 1
    Angers, France
  • Facility 1
    Bordeaux, France
  • Facility 1
    Caen, France
  • Facility 1
    Clermont-Ferrand, France
  • Facility 1
    Dijon, France
  • Facility 1
    Lille, France
  • Facility 1
    Lyon, France
  • Facility 1
    Marseille, France
  • Facility 1
    Nice, France
  • Facility 1
    Paris, France
  • Facility 2
    Paris, France
  • Facility 1
    Strasbourg, France
  • Facility 1
    Vandoeuvre Les Nancy, France
  • Facility 1
    Villejuif, France
  • Facility 1
    Essen, Germany
  • Facility 1
    Hannover, Germany
  • Facility 1
    Leipzig, Germany
  • Facility 1
    Mainz, Germany
  • Facility 1
    Munchen, Germany
  • Facility 1
    Tubingen, Germany
  • Facility 1
    Wurzburg, Germany
  • Facility 1
    Catania, Italy
  • Facility 1
    Livorno, Italy
  • Facility 1
    Milano, Italy
  • Facility 2
    Milano, Italy
  • Facility 3
    Milano, Italy
  • Facility 4
    Milano, Italy
  • Facility 5
    Milano, Italy
  • Facility 1
    Monserrato, Italy
  • Facility 1
    Napoli, Italy
  • Facility 1
    Padova, Italy
  • Facility 1
    Pisa, Italy

Showing the first 100 of 155 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Taylor MH, Takahashi S, Capdevila J, Tahara M, Leboulleux S, Kiyota N, Dutcus CE, Xie R, Robinson B, Sherman S, Habra MA, Elisei R, Wirth LJ. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. Thyroid. 2021 Aug;31(8):1226-1234. doi: 10.1089/thy.2020.0779. Epub 2021 Apr 29. PubMed 33637020 ↗
  • Tahara M, Kiyota N, Hoff AO, Badiu C, Owonikoko TK, Dutcus CE, Suzuki T, Ren M, Wirth LJ. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2021 Apr;147:51-57. doi: 10.1016/j.ejca.2020.12.032. Epub 2021 Feb 19. PubMed 33611104 ↗
  • Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, Dutcus CE, Gianoukakis A. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019 Jan;106:61-68. doi: 10.1016/j.ejca.2018.10.002. Epub 2018 Nov 22. PubMed 30471649 ↗
  • Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, Dutcus CE, Hihara T, McGrath S, Matijevic M, Kadowaki T, Funahashi Y, Sherman SI. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer. 2017 Apr;75:213-221. doi: 10.1016/j.ejca.2017.01.013. Epub 2017 Feb 24. PubMed 28237867 ↗
  • Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab. 2016 Nov;101(11):4103-4109. doi: 10.1210/jc.2015-3989. Epub 2016 Aug 22. PubMed 27548104 ↗
  • Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Kawai Y, Wirth L, Robinson B, Sherman S, Suzuki T, Fujino K, Gupta A, Hayato S, Tahara M. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 2015 Dec;106(12):1714-21. doi: 10.1111/cas.12826. Epub 2015 Nov 2. PubMed 26426092 ↗
  • Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30. doi: 10.1056/NEJMoa1406470. PubMed 25671254 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Nov 2013, 31 months.

Results were first posted in Dec 2016, 3 years after primary completion.

Of 19 phase 3 interventional studies under Thyroid Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 106. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2011
First posted
Mar 23, 2011
StartActual
Mar 17, 2011
Primary completionActual
Nov 15, 2013
CompletionActual
Mar 19, 2019
Results first posted
Dec 12, 2016
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01321554
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Mar 23, 2011
Start date
Mar 17, 2011
Primary completion
Nov 15, 2013
Completion
Mar 19, 2019
Results posted
Dec 12, 2016
Last update
Jun 22, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion